All In Biotech

NDA 021366 · Astrazeneca

Crestor

Rosuvastatin Calcium · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Aug 12, 2003

Approved uses

7

Original approval plus efficacy supplements

Registered trials

824

189 Phase 3, 59 recruiting

FAERS reports

207,891

140,698 serious, 12,446 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 23, 2026.

CRESTOR is indicated: • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events. • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): ∘ in adults with hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia. CRESTOR is an HMG Co‑A reductase inhibitor (statin) indicated: ( 1 ) • To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events. • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C): ∘ in adults with primary hypercholesterolemia. ∘ and slow the progression of atherosclerosis in adults. ∘ in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ∘ in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the treatment of adults with: ∘ Primary dysbetalipoproteinemia. ∘ Hypertriglyceridemia.

Mechanism: CRESTOR is an inhibitor of HMG‑CoA reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • CRESTOR · ROSUVASTATIN CALCIUM EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
  • CRESTOR · ROSUVASTATIN CALCIUM EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
  • CRESTOR · ROSUVASTATIN CALCIUM EQ 40MG BASE · TABLET, ORAL · Prescription · TE AB
  • CRESTOR · ROSUVASTATIN CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Rosuvastatin" as an intervention, any sponsor and status, largest first.

All 824 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue12,643
  • nausea10,873
  • diarrhoea10,009
  • drug ineffective9,957
  • dyspnoea9,810
  • off label use9,289
  • myalgia9,259
  • pain8,962
  • headache8,466
  • dizziness8,274
  • arthralgia7,767
  • asthenia7,654

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,921
20052,047
20063,055
20072,421
20083,898
20095,904
20107,391
20119,524
201211,040
20137,390
20148,106
201510,275
201610,288
20179,901
201811,123
201911,854
202011,540
202111,928
202212,119
202312,833
202413,919
202515,891
202612,523

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Crestor (Rosuvastatin Calcium)

2024 spending

$31.9M

Beneficiaries

13,827

54,565 claims

Per beneficiary

$2,309

$8.79 per unit

View as table
YearSpending
2020$54,380,618
2021$48,218,264
2022$42,887,889
2023$38,872,959
2024$31,919,838

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,245 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.